Yes, Cologuard is a Stool-Based Test for Colorectal Cancer Screening
Cologuard is a multitarget stool DNA test (sDNA-FIT) that combines DNA biomarker detection with a fecal immunochemical test (FIT) component, collected from a complete bowel movement at home and mailed to a laboratory for analysis. 1, 2
How Cologuard Works
The test detects:
- DNA biomarkers shed from colorectal cancer cells and precancerous lesions into stool
- Hemoglobin (blood) in stool through the integrated FIT component
This is distinct from other stool-based tests like standalone FIT (which only detects blood) or guaiac-based tests (which use chemical detection of blood). 1
Collection and Testing Process
Key implementation details:
- Requires collection of an entire bowel movement (not just a sample)
- No dietary or medication restrictions needed before collection 1
- Performed at home with no bowel preparation required
- Sample is mailed directly to the laboratory
- Single stool collection (unlike high-sensitivity gFOBT which requires 3 separate samples) 1
Screening Performance
The next-generation multitarget stool DNA test demonstrates:
- 93.9% sensitivity for colorectal cancer 3
- 43.4% sensitivity for advanced precancerous lesions 3
- 90.6% specificity for advanced neoplasia 3
The original Cologuard formulation showed 92% sensitivity for colorectal cancer and notably 40% sensitivity for sessile serrated polyps >1 cm, which FIT cannot detect. 2
Recommended Screening Interval
The test is FDA-approved and recommended at 3-year intervals by both USPSTF and Centers for Medicare & Medicaid Services. 1, 2 This contrasts with annual FIT testing.
Critical Follow-Up Requirement
Any positive Cologuard result requires follow-up colonoscopy within 6 months to complete the screening process. 4 This is non-negotiable for screening to be effective.
Real-World Adherence Concerns
A significant pitfall: Only 44% of patients with positive Cologuard results complete follow-up colonoscopy within 12 months 5, and among those who do, only 38.5% have significant lesions found 6. This poor adherence undermines the entire screening benefit and represents a major implementation challenge requiring:
- Enhanced patient education about the necessity of colonoscopy after positive results
- Streamlined referral pathways
- Active tracking systems 5
Comparison to Other Stool Tests
Advantages over FIT alone:
- Higher single-test sensitivity for cancer (93.9% vs 67.3%) 3
- Detects serrated polyps that FIT misses 2
- Less frequent testing required (every 3 years vs annually)
Disadvantages compared to FIT:
- Lower specificity (90.6% vs 94.8%), meaning more false positives 3
- Specificity decreases with age (only 83% in adults >65 years) 2
- Approximately 10 times more expensive ($500-600 vs ~$20 for FIT) 2, 7
- Generates more colonoscopy referrals per screening episode 1
Clinical Positioning
The USPSTF and major guidelines recommend Cologuard as one of several acceptable screening options for average-risk adults starting at age 45. 1, 4 The most recent 2026 American Cancer Society guideline reaffirms this, classifying it among "preferred stool-based screening options" alongside FIT. 4
Modeling studies show that annual FIT is more effective and less costly than Cologuard every 3 years, making FIT the preferred choice for organized screening programs. 2 However, Cologuard may be particularly appropriate for:
- Patients aged 50-65 who want noninvasive testing with very high cancer sensitivity (better specificity in this age group) 2
- Patients who decline or won't adhere to annual FIT testing 2
- Those seeking detection of serrated lesions 2
The most effective screening test is the one the patient actually completes 4, so offering multiple options including Cologuard supports informed choice and may improve overall screening participation.